Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Peter Blume-Jensen Insider Profile
4 Followers
Peter Blume-Jensen, President & CEO, Director at Acrivon Therapeutics, Inc., holds 2.66M shares in Acrivon Therapeutics, Inc. (Ticker: ACRV).
Peter Blume-Jensen has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Peter Blume-Jensen's holdings
Insider Roles
President & CEO, Director
Roles that Peter Blume-Jensen holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Peter Blume-Jensen
Peter Blume-Jensen's Trading History
List of latest transactions for each holding click on a transaction to see Peter Blume-Jensen's performance on stock
You May Also Like
Peter Blume-Jensen insider profile FAQ
What is the percentage of profitable transactions made by Peter Blume-Jensen?
The percentage of profitable transactions made by Peter Blume-Jensen is ―.
What is the average return per transaction made by Peter Blume-Jensen?
The average return per transaction made by Peter Blume-Jensen is ―.
What stocks does Peter Blume-Jensen hold?
Peter Blume-Jensen holds: ACRV stocks.
What was Peter Blume-Jensen’s latest transaction?
Peter Blume-Jensen latest transaction was an Uninformative Sell of $128.22K.
What was Peter Blume-Jensen's most profitable transaction?
Peter Blume-Jensen’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Peter Blume-Jensen's role in Acrivon Therapeutics, Inc.?
Peter Blume-Jensen's role in Acrivon Therapeutics, Inc. is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.